TY - JOUR AU - West, N. Winston AU - Garcia-Vargas, Aileen AU - Chalfant, Charles E. AU - Park, Margaret A. PY - 2013 DA - 2013/05/24 TI - OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2 JO - BMC Cancer SP - 256 VL - 13 IS - 1 AB - Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-13-256 DO - 10.1186/1471-2407-13-256 ID - West2013 ER -